User:Kleinsorg/main

From 2010.igem.org

(Difference between revisions)
Line 242: Line 242:
</a>
</a>
-
<a class="piclinks" href="" onMouseOver="mouseOver(6); writeText('Thirteen students and nine advisors are working on this four month project. We split up into several subgroups whose focus and results you can follow on the Notebook and Project pages. If you want to know more about the subgroups and the people involved, meet us on our Team page and lets get to know each other better at the Jamboree in Boston. ')" onMouseOut="mouseOut(6)" onMouseDown="mouseDown(6)" onMouseUp="mouseUp(6)">
+
<a class="piclinks" onMouseOver="mouseOver(6); writeText('Thirteen students and nine advisors are working on this four month project. We split up into several subgroups whose focus and results you can follow on the Notebook and Project pages. If you want to know more about the subgroups and the people involved, meet us on our Team page and lets get to know each other better at the Jamboree in Boston. ')" onMouseOut="mouseOut(6)" onMouseDown="mouseDown(6)" onMouseUp="mouseUp(6)">
<img id="pic6"  border=0 src="http://igem.bioquant.uni-heidelberg.de/mediawiki/images/1/16/Sponsors.png" />
<img id="pic6"  border=0 src="http://igem.bioquant.uni-heidelberg.de/mediawiki/images/1/16/Sponsors.png" />
</a>
</a>

Revision as of 13:13, 30 September 2010

iGEM Heidelberg Mission 2010: miBricks


The key to successful gene therapy is integration of tissue specificity and fine-tuned target gene expression. The iGEM Team Heidelberg 2010 unlocks the world of synthetic microRNAs, since focusing solely on DNA has often been inconvenient for medical purposes. We engineered a toolkit for standardized measurements of interactions between artificial miRNAs and their binding sites. From this data we were able to compute an in silico model integrating binding site properties and knockdown percentages. Thus, the expression level of any gene of choice could be arbitrarily adjusted by employing the corresponding binding site design. To produce tissue specific miRNA gene shuttles, we developed an evolution-based method for synthesis of new adeno associated viruses. This enabled us to overcome the natural limitations of virus selectivity. In the future, miBricks could be applied for treatment of diseases like Diabetes and Hemophilia, opening the doors to new Synthetic Biology based medical approaches.














The iGEM 2010 Heidelberg - Team


Retrieved from "http://2010.igem.org/User:Kleinsorg/main"